Paradox Immunotherapeutics

Profile

Paradox Immunotherapeutics is a venture-backed, clinical-inflection biotech tackling protein misfolding diseases - devastating conditions with limited treatment options and high mortality. Backed by a team with a proven track record, including the design of an antibody that led to a $1.2B acquisition deal in 2021, Paradox uses a proprietary platform requiring only native protein structure to develop antibodies that selectively engage pathological proteins while sparing healthy biology. Lead program LX-96 is advancing to Phase 1b in κ AL amyloidosis; a second program, LX-97, is on track for IND.

paradox immunotherapeutics

Website

paradoximmuno.com

Contact


Event details

Date: June 22 - 25, 2026

Event contact

Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe

Participants

23 in total